JPH0645643B2 - エキナセアプルプレアまたはエキナセアアングスティフォリアの細胞培養物からの免疫刺激作用性ポリサッカライド、その製造方法及びこれを含む製剤 - Google Patents
エキナセアプルプレアまたはエキナセアアングスティフォリアの細胞培養物からの免疫刺激作用性ポリサッカライド、その製造方法及びこれを含む製剤Info
- Publication number
- JPH0645643B2 JPH0645643B2 JP61280949A JP28094986A JPH0645643B2 JP H0645643 B2 JPH0645643 B2 JP H0645643B2 JP 61280949 A JP61280949 A JP 61280949A JP 28094986 A JP28094986 A JP 28094986A JP H0645643 B2 JPH0645643 B2 JP H0645643B2
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- polysaccharides
- eluent
- precipitate
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 115
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 114
- 238000004113 cell culture Methods 0.000 title claims abstract description 14
- 230000003308 immunostimulating effect Effects 0.000 title claims description 21
- 235000014134 echinacea Nutrition 0.000 title claims description 15
- 240000004530 Echinacea purpurea Species 0.000 title claims description 8
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 244000133098 Echinacea angustifolia Species 0.000 title claims description 7
- 150000004676 glycans Chemical class 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000008569 process Effects 0.000 claims abstract description 6
- 150000004804 polysaccharides Chemical class 0.000 claims description 110
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 47
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 25
- 239000002244 precipitate Substances 0.000 claims description 22
- 238000001556 precipitation Methods 0.000 claims description 20
- 241000196324 Embryophyta Species 0.000 claims description 17
- 239000011780 sodium chloride Substances 0.000 claims description 17
- 230000007935 neutral effect Effects 0.000 claims description 16
- 239000003480 eluent Substances 0.000 claims description 15
- 150000004805 acidic polysaccharides Chemical class 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 13
- 229910021641 deionized water Inorganic materials 0.000 claims description 13
- 239000012153 distilled water Substances 0.000 claims description 13
- 229920001284 acidic polysaccharide Polymers 0.000 claims description 12
- 238000005571 anion exchange chromatography Methods 0.000 claims description 12
- 239000007858 starting material Substances 0.000 claims description 12
- 238000002955 isolation Methods 0.000 claims description 10
- 238000000746 purification Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 9
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical group OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 8
- 206010020649 Hyperkeratosis Diseases 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- 238000002523 gelfiltration Methods 0.000 claims description 7
- 229960001438 immunostimulant agent Drugs 0.000 claims description 7
- 239000012528 membrane Substances 0.000 claims description 7
- 239000012465 retentate Substances 0.000 claims description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 7
- 239000003022 immunostimulating agent Substances 0.000 claims description 6
- 239000012466 permeate Substances 0.000 claims description 6
- 238000004114 suspension culture Methods 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 238000011026 diafiltration Methods 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- 239000006285 cell suspension Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 229920002492 poly(sulfone) Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 239000001632 sodium acetate Substances 0.000 claims description 3
- 235000017281 sodium acetate Nutrition 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 3
- 229920001817 Agar Polymers 0.000 claims description 2
- 239000008272 agar Substances 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 238000005352 clarification Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 238000001471 micro-filtration Methods 0.000 claims description 2
- 230000006920 protein precipitation Effects 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 238000013060 ultrafiltration and diafiltration Methods 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 4
- 238000001641 gel filtration chromatography Methods 0.000 claims 4
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims 2
- 239000001166 ammonium sulphate Substances 0.000 claims 2
- 235000011130 ammonium sulphate Nutrition 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000012228 culture supernatant Substances 0.000 claims 1
- 238000011033 desalting Methods 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000012869 ethanol precipitation Methods 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 16
- 239000002609 medium Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- 210000003714 granulocyte Anatomy 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000003850 cellular structure Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 239000012506 Sephacryl® Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000005349 anion exchange Methods 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 210000003918 fraction a Anatomy 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229920000189 Arabinogalactan Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 206010022998 Irritability Diseases 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 239000004236 Ponceau SX Substances 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 235000019312 arabinogalactan Nutrition 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- OVSKIKFHRZPJSS-DOMIDYPGSA-N 2-(2,4-dichlorophenoxy)acetic acid Chemical compound OC(=O)[14CH2]OC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-DOMIDYPGSA-N 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001579678 Panthea coenobita Species 0.000 description 1
- 108010064851 Plant Proteins Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 235000021118 plant-derived protein Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 125000000969 xylosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)CO1)* 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Polymers & Plastics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Plant Substances (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853541945 DE3541945A1 (de) | 1985-11-27 | 1985-11-27 | Immunstimulierend wirkende polysaccharide aus zellkulturen von echinacea purpurea (l.) moench und echinacea angustifolia, d.c. verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen |
| DE3541945.8 | 1985-11-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62209101A JPS62209101A (ja) | 1987-09-14 |
| JPH0645643B2 true JPH0645643B2 (ja) | 1994-06-15 |
Family
ID=6286997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP61280949A Expired - Lifetime JPH0645643B2 (ja) | 1985-11-27 | 1986-11-27 | エキナセアプルプレアまたはエキナセアアングスティフォリアの細胞培養物からの免疫刺激作用性ポリサッカライド、その製造方法及びこれを含む製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4857512A (en, 2012) |
| EP (1) | EP0225496B1 (en, 2012) |
| JP (1) | JPH0645643B2 (en, 2012) |
| AT (1) | ATE76434T1 (en, 2012) |
| DE (2) | DE3541945A1 (en, 2012) |
| ES (1) | ES2039193T3 (en, 2012) |
| GR (1) | GR3005297T3 (en, 2012) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5296245A (en) * | 1987-02-26 | 1994-03-22 | Bio Polymers Pty. Ltd. | Plant gum material and use thereof in food products |
| DE3855758T2 (de) * | 1987-02-26 | 1997-07-31 | Bio Polymers Pty Ltd | Substanz aus pflanzlichem gummi und ihre verwendung in lebensmitteln |
| US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
| US6271001B1 (en) | 1995-03-23 | 2001-08-07 | Bio Polymers Pty. Ltd. | Cultured plant cell gums for food, pharmaceutical, cosmetic and industrial applications |
| US6379714B1 (en) | 1995-04-14 | 2002-04-30 | Pharmaprint, Inc. | Pharmaceutical grade botanical drugs |
| FR2734578B1 (fr) * | 1995-05-23 | 1997-08-14 | Agronomique Inst Nat Rech | Enzyme degradant le rhamnogalacturonane ii, procedes d'obtention de cette enzyme et du rhamnogalacturonane ii et utilisation de cette enzyme |
| WO1999008705A1 (en) * | 1997-08-20 | 1999-02-25 | Brigham And Women's Hospital | Capsular polysaccharides from enterococci |
| US6722062B2 (en) | 1997-08-20 | 2004-04-20 | The Brigham And Women's Hospital, Inc. | Capsular polysaccharides from enterococci |
| US6096307A (en) * | 1997-12-11 | 2000-08-01 | A. Glenn Braswell | Compositions for immunostimulation containing Echinacea angustofolia, bromelain, and lysozyme |
| AU2001261317A1 (en) * | 2000-05-09 | 2001-11-20 | Pharmanex, Llc | Immunostimulant compositions and associated methods |
| US6991811B1 (en) | 2000-05-19 | 2006-01-31 | Access Business Group International Llc | Echinacea induction of phase II enzymes |
| US6306443B1 (en) | 2000-06-20 | 2001-10-23 | Amway Corporation | Method of increasing concentrations of caffeic acid derivatives and alkylamides and compositions containing the same |
| JP2002012546A (ja) * | 2000-06-29 | 2002-01-15 | Noevir Co Ltd | 皮膚外用剤 |
| RU2276157C2 (ru) * | 2000-11-27 | 2006-05-10 | Бомсунд Групо Асесор, С.Л. | Полисахарид с иммуностимулирующей активностью, способ его получения и применение |
| HUP0400647A2 (hu) * | 2000-11-27 | 2004-07-28 | Bomsund Grupo Asesor, S.L. | Immunstimuláló aktivitással rendelkező poliszacharidszármazék, eljárás az előállítására és ezt tartalmazó gyógyszerkészítmények |
| RU2208440C2 (ru) * | 2001-07-20 | 2003-07-20 | Иркутский институт химии им. А.Е. Фаворского СО РАН | Средство, обладающее противоанемической и иммуномодуляторной активностью |
| ITMI20021691A1 (it) * | 2002-07-30 | 2004-01-30 | Indena Spa | Estratti di echinacea angustifolia |
| ITMI20021692A1 (it) * | 2002-07-30 | 2002-10-29 | Indena Spa | Polisaccaride di echinacea angustifolia. |
| CN1297568C (zh) * | 2003-08-08 | 2007-01-31 | 吉林威威药业股份有限公司 | 一种松果菊多糖、其制备方法及其在制备治疗抗病毒、抗菌及抗sars药物上的用途 |
| US20050220846A1 (en) | 2004-04-05 | 2005-10-06 | Puntenney Steven B | Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function |
| WO2006002493A1 (en) * | 2004-07-07 | 2006-01-12 | Mediherb Holdings Ltd | An echinacea formulation |
| US20070154581A1 (en) * | 2005-12-30 | 2007-07-05 | Kumar Kalyani M | Composition and method for enhancing or stimulating the immune system |
| WO2014007606A1 (en) | 2012-07-05 | 2014-01-09 | N.V. Nutricia | Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour |
| US8920855B1 (en) | 2012-10-30 | 2014-12-30 | Setem Hemth, Inc | Methods of topically treating tinnitus and related disorders |
| PT3110437T (pt) | 2014-02-12 | 2018-01-16 | Omnigen Res Llc | Composição e método para promover a redução do stress térmico em animais |
| CN105037574B (zh) * | 2015-07-13 | 2017-07-28 | 青岛农业大学 | 一种超声提取紫锥菊多糖的方法 |
| WO2017044832A1 (en) | 2015-09-09 | 2017-03-16 | Omnigen Research, Llc | A composition and/or combination for aquaculture |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1560202A (en, 2012) * | 1963-04-23 | 1969-03-21 | ||
| DE2721014A1 (de) * | 1977-05-10 | 1978-11-16 | Reith Franz Josef | Echinacea und milchsaeurederivate enthaltendes arzneimittel |
| DE3042491A1 (de) * | 1980-11-11 | 1982-07-15 | Wagner, Hildebert, Prof. Dr., 8211 Breitbrunn | Niedermolekulare polysaccaride aus pflanzen der compositen-familie, verfahren zu ihrer gewinnung und sie enthaltende pharmazeutische zubereitungen |
| AU8334682A (en) * | 1981-04-30 | 1982-11-24 | Zenyaku Kogyo Kabushiki Kaisha | Polysaccharide ps=a isolated from the plant of genus epimedium violaceium morr. et decne., process for its preparation, and infection-preventing agent and immunostimulating agent containing the ploysaccharide as effective ingredient |
| JPS5834803A (ja) * | 1981-08-24 | 1983-03-01 | Seikagaku Kogyo Co Ltd | 血液型活性複合多糖及びその製造法 |
| US4614733A (en) * | 1981-12-31 | 1986-09-30 | Kureha Kagaku Kogyo Kabushiki Kaisha | Polysaccharides pharmaceutical compositions and the use thereof |
| HU188311B (en) * | 1982-03-04 | 1986-04-28 | Szendrei,Kalman,Hu | Process for producing biologically active polisaccharide concentrates and pharmaceutical compositions containing them as active agents |
| DE3217214A1 (de) * | 1982-05-07 | 1983-11-10 | Wagner, Hildebert, Prof. Dr., 8211 Breitbrunn | Polysaccharide aus pflanzen der compositen-familie, verfahren zu ihrer gewinnung und sie enthaltende pharmazeutische zubereitungen |
| JPH0424791A (ja) * | 1990-05-15 | 1992-01-28 | Sharp Corp | 計算機言語処理システム |
| JPH04316048A (ja) * | 1991-04-15 | 1992-11-06 | Nikon Corp | フォトマスクの検査方法、フォトマスクの製造方法及び半導体素子製造方法 |
| JP2999021B2 (ja) * | 1991-07-26 | 2000-01-17 | ユニチカ株式会社 | 迷彩加工テント地 |
-
1985
- 1985-11-27 DE DE19853541945 patent/DE3541945A1/de not_active Withdrawn
-
1986
- 1986-11-10 AT AT86115584T patent/ATE76434T1/de not_active IP Right Cessation
- 1986-11-10 ES ES198686115584T patent/ES2039193T3/es not_active Expired - Lifetime
- 1986-11-10 EP EP86115584A patent/EP0225496B1/de not_active Expired - Lifetime
- 1986-11-10 DE DE8686115584T patent/DE3685411D1/de not_active Expired - Lifetime
- 1986-11-21 US US06/933,482 patent/US4857512A/en not_active Expired - Fee Related
- 1986-11-27 JP JP61280949A patent/JPH0645643B2/ja not_active Expired - Lifetime
-
1992
- 1992-07-29 GR GR920401629T patent/GR3005297T3/el unknown
Non-Patent Citations (2)
| Title |
|---|
| Ａｒｚｎｅｉｍ．−Ｆｏｒｓｃｈ．／ＤｒｕｇＲｅｓ．，３５（▲ＩＩ▼）．１０６９−１０７５（１９８５） |
| Ａｒｚｎｅｉｍ−Ｆｏｒｓｃｈ．／ＤｒｕｇＲｅｓ．，３４（▲Ｉ▼），６５９−６６１（１９８４） |
Also Published As
| Publication number | Publication date |
|---|---|
| GR3005297T3 (en, 2012) | 1993-05-24 |
| DE3685411D1 (de) | 1992-06-25 |
| EP0225496B1 (de) | 1992-05-20 |
| DE3541945A1 (de) | 1987-06-04 |
| ATE76434T1 (de) | 1992-06-15 |
| EP0225496A3 (en) | 1988-01-13 |
| US4857512A (en) | 1989-08-15 |
| JPS62209101A (ja) | 1987-09-14 |
| ES2039193T3 (es) | 1993-09-16 |
| EP0225496A2 (de) | 1987-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0645643B2 (ja) | エキナセアプルプレアまたはエキナセアアングスティフォリアの細胞培養物からの免疫刺激作用性ポリサッカライド、その製造方法及びこれを含む製剤 | |
| KR100831408B1 (ko) | 미세조류로부터 얻은 유효 면역자극제 | |
| JP4010768B2 (ja) | アンジェリカ・ギガス・ナカイから精製した新規のペクチン質多糖類とその精製方法およびその免疫刺激剤としての使用 | |
| JP3798425B2 (ja) | ヒト細胞への菌付着の遮断 | |
| US4886666A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| US4843067A (en) | Polysaccharide containing pharmaceutical composition for increasing the immune function | |
| RU2308460C2 (ru) | Полисахарид из корней echinacea angustifolia, способ его получения, фармацевтическая композиция | |
| JPH0539305A (ja) | アストラガルス・メンブラナセウスから抽出した免疫 変調性多糖類及びこれらを含有する薬剤組成物 | |
| US4944946A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| CN105294878B (zh) | 一种桑枝抗肿瘤活性多糖rmpw‑1的制备方法 | |
| US4985247A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| JPH0148920B2 (en, 2012) | ||
| JPH0379602A (ja) | 免疫刺激・抗増殖作用を有する多糖類、その製造方法及びこの物質を含有した薬剤 | |
| CN105294879B (zh) | 一种桑枝抗肿瘤活性多糖rmpw‑2的制备方法 | |
| US4944945A (en) | Pharmaceutical composition for inhibiting viruses and increasing immune function (PII) | |
| DE19817177A1 (de) | Pflanzliche Polysaccharide mit immunstimulierender Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel | |
| NO850152L (no) | Fremgangsmaate ved fremstilling av human, endogen cancerregulerende faktor. | |
| KR100772007B1 (ko) | 마크로파지 활성화 또는 항암용 알로에 조성물 | |
| EP0397172B1 (en) | Composition for curing autoimmune disease |